Inquiry Basket
Loading ......
Filter By Product Search for
RPS6KA6
RPS6KA6 Full Name
ribosomal protein S6 kinase, 90kDa, polypeptide 6
RPS6KA6 Introduction
RPS6KA6 encodes a serine/threonine protein kinase belonging to the p90 RSK family, functioning downstream of the Ras–RAF–MEK–ERK signaling cascade. Unlike other RSK family members, RSK4 exhibits distinct tissue distribution, regulatory mechanisms, and transcriptional diversity, making its biological role more complex than initially appreciated. Rather than acting as a universal promoter or suppressor of cell growth, RSK4 integrates extracellular signaling with intracellular responses that regulate proliferation, differentiation, apoptosis, and cellular stress adaptation. This functional flexibility has made RPS6KA6 an increasingly important target in cancer biology, kinase signaling research, and therapeutic discovery.
Functionally, RSK4 acts as a downstream effector of ERK activation and phosphorylates numerous substrates involved in cell-cycle regulation, gene transcription, protein synthesis, and survival signaling. The protein contains two conserved kinase domains that cooperate through sequential phosphorylation events, allowing precise control of kinase activation and substrate recognition. Recent transcriptomic analyses have demonstrated that RPS6KA6 generates multiple mRNA transcript isoforms through alternative first exon usage, producing protein variants with distinct expression patterns in normal tissues and tumors. These findings help explain why different studies have reported seemingly opposite biological functions for RSK4. Structural and biochemical investigations have further revealed key regulatory mechanisms within its C-terminal kinase domain, providing valuable insights for the development of selective RSK-family inhibitors. Beyond oncology, emerging evidence indicates that RSK4 also contributes to skeletal muscle differentiation and normal tissue development, expanding its relevance to developmental and regenerative biology.
Aberrant expression or dysregulation of RPS6KA6 has been linked to multiple human malignancies, including breast cancer, colorectal cancer, lung cancer, glioma, esophageal squamous cell carcinoma, ovarian cancer, renal cell carcinoma, endometrial cancer, and leukemia. In many experimental models, reduced RSK4 activity is associated with enhanced tumor cell proliferation, migration, and invasion, supporting a tumor-suppressive function. However, accumulating evidence indicates that specific transcript isoforms and tissue-specific signaling environments can produce different biological outcomes, explaining why RSK4 may exhibit either tumor-suppressive or tumor-promoting characteristics depending on cellular context. This evolving understanding has shifted current research toward isoform-specific functional analysis rather than treating RSK4 as a single-function kinase. As knowledge of its regulatory mechanisms continues to expand, RPS6KA6 is increasingly recognized as a promising biomarker candidate and therapeutic target for precision oncology, while its emerging roles in muscle biology and MAPK-associated disorders continue to broaden its translational significance.
Alternate Names for RPS6KA6
RPS6KA6; ribosomal protein S6 kinase, 90kDa, polypeptide 6; RSK4; PP90RSK4; ribosomal protein S6 kinase alpha-6; RSK-4; p90RSK6; p90-RSK 6; S6K-alpha 6; S6K-alpha-6; ribosomal S6 kinase 4; 90 kDa ribosomal protein S6 kinase 6;
Loading ......
